Published • loading... • Updated
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
Summary by Benzinga
3 Articles
3 Articles
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections. Experts from the UK, Greece and Switzerland to share preclinical insights on BV100's activity against CRABC on Sunday, April 19, 2026. Bi…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
